SYN-004 clinical trials
Also written SYN-004.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses SYN-004 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYN-004
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Theriva Biologics, Inc. (2) · Synermore Biologics Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses SYN-004 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an IleostomyCompletedPhase 1/2Theriva Biologics, Inc.NCT02473640Written as SYN-004
- A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTICompletedPhase 2Theriva Biologics, Inc.NCT02563106Written as SYN-004
- Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid TumorsCompletedPhase 1Synermore Biologics Co., Ltd.NCT02391727Written as SYN004